[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR086051A1 - Metodo para tratar el cancer colorrectal, composicion que comprende aflibercept, acido folinico, 5-fluorouracilo (5-fu) e irinotecano (folfiri), articulo manufacturado, kit - Google Patents

Metodo para tratar el cancer colorrectal, composicion que comprende aflibercept, acido folinico, 5-fluorouracilo (5-fu) e irinotecano (folfiri), articulo manufacturado, kit

Info

Publication number
AR086051A1
AR086051A1 ARP120101420A ARP120101420A AR086051A1 AR 086051 A1 AR086051 A1 AR 086051A1 AR P120101420 A ARP120101420 A AR P120101420A AR P120101420 A ARP120101420 A AR P120101420A AR 086051 A1 AR086051 A1 AR 086051A1
Authority
AR
Argentina
Prior art keywords
folinic acid
aflibercept
composition
irinotecano
folfiri
Prior art date
Application number
ARP120101420A
Other languages
English (en)
Inventor
Remi Castan
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46001286&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR086051(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of AR086051A1 publication Critical patent/AR086051A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/178—Lectin superfamily, e.g. selectins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una composición farmacéutica que comprende aflibercept, ácido folínico, 5-fluorouracilo (5-FU) e irinotecano (FOLFIRI) útil para el tratamiento del cáncer colorrectal (CRC).Reivindicación 1: Un método para tratar el cáncer colorrectal (CRC) o un síntoma del cáncer colorrectal (CRC) en un paciente que lo necesite, comprendiendo dicho método administrar a dicho paciente cantidades terapéuticamente eficaces de aflibercept, ácido folínico, 5-fluorouracilo (5-FU) e irinotecano. Reivindicación 24: Una composición que comprende cantidades terapéuticamente eficaces de aflibercept en combinación con ácido folínico, 5-fluorouracilo (5-FU) e irinotecano para tratar pacientes con CRC, en la que las administraciones de aflibercept, ácido folínico, 5-fluorouracilo (5-FU) e irinotecano se espacian a lo largo de un periodo de tiempo para obtener la máxima eficacia de la combinación.
ARP120101420A 2011-04-26 2012-04-25 Metodo para tratar el cancer colorrectal, composicion que comprende aflibercept, acido folinico, 5-fluorouracilo (5-fu) e irinotecano (folfiri), articulo manufacturado, kit AR086051A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11305490 2011-04-26
EP11306154 2011-09-15

Publications (1)

Publication Number Publication Date
AR086051A1 true AR086051A1 (es) 2013-11-13

Family

ID=46001286

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120101420A AR086051A1 (es) 2011-04-26 2012-04-25 Metodo para tratar el cancer colorrectal, composicion que comprende aflibercept, acido folinico, 5-fluorouracilo (5-fu) e irinotecano (folfiri), articulo manufacturado, kit

Country Status (38)

Country Link
US (1) US11033606B2 (es)
EP (2) EP3210617A1 (es)
JP (1) JP6114257B2 (es)
KR (2) KR102002653B1 (es)
CN (1) CN103608029A (es)
AR (1) AR086051A1 (es)
AU (1) AU2012247530B2 (es)
BR (1) BR112013027356A2 (es)
CA (1) CA2833592A1 (es)
CL (1) CL2013003082A1 (es)
CO (1) CO6811861A2 (es)
CR (1) CR20130547A (es)
CY (1) CY1120382T1 (es)
DK (1) DK2701724T3 (es)
DO (1) DOP2013000248A (es)
EA (1) EA025182B1 (es)
EC (1) ECSP13013044A (es)
ES (1) ES2637074T3 (es)
GT (1) GT201300260A (es)
HR (1) HRP20171216T1 (es)
HU (1) HUE034288T2 (es)
IL (2) IL228947B (es)
JO (1) JO3283B1 (es)
LT (1) LT2701724T (es)
MA (1) MA35130B1 (es)
MX (1) MX341348B (es)
NI (1) NI201300112A (es)
PE (2) PE20140616A1 (es)
PL (1) PL2701724T3 (es)
PT (1) PT2701724T (es)
RS (1) RS56177B1 (es)
SG (2) SG194613A1 (es)
SI (1) SI2701724T1 (es)
TW (1) TWI599369B (es)
UA (1) UA114708C2 (es)
UY (1) UY34036A (es)
WO (1) WO2012146610A1 (es)
ZA (1) ZA201308821B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
AU2013202947B2 (en) * 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
EA201590305A1 (ru) * 2012-08-02 2015-06-30 Санофи Изделие производства, включающее афлиберцепт или зив-афлиберцепт
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
DK3170005T3 (da) * 2014-07-18 2019-07-08 Sanofi Sa Fremgangsmåde til forudsigelse af resultatet af en behandling med aflibercept hos en patient, der mistænkes for at lide af cancer
WO2016044041A1 (en) * 2014-09-16 2016-03-24 Regeneron Pharmaceuticals, Inc. Predictive and prognostic biomarkers related to anti-angiogenic therapy of metastatic colorectal cancer
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
SI3337467T1 (sl) 2015-08-20 2021-03-31 Ipsen Biopharm Ltd. Ash Road Kombinacijska terapija, ki vsebuje liposomski irinotekan in zaviralec PARP za zdravljenje raka
CN108495629A (zh) 2015-08-21 2018-09-04 益普生生物制药有限公司 使用包含脂质体伊立替康和奥沙利铂的组合疗法治疗转移性胰腺癌的方法
KR101936049B1 (ko) * 2015-10-15 2019-01-08 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 생산방법
US11066465B2 (en) 2015-12-30 2021-07-20 Kodiak Sciences Inc. Antibodies and conjugates thereof
KR102652347B1 (ko) * 2016-01-25 2024-03-27 사노피 혈장 바이오마커 수준의 측정에 의해 암을 앓고 있는 것으로 의심되는 환자의 아플리베르셉트로의 치료 결과를 예측하는 방법
CN110402163A (zh) 2016-11-02 2019-11-01 易普森生物制药有限公司 使用包括脂质体伊立替康、奥沙利铂、5-氟尿嘧啶(和甲酰四氢叶酸)的组合疗法治疗胃癌
EP3758737A4 (en) 2018-03-02 2022-10-12 Kodiak Sciences Inc. IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF
CN112739323A (zh) 2018-05-10 2021-04-30 瑞泽恩制药公司 含有高浓度vegf受体融合蛋白的制剂
WO2019229115A1 (en) * 2018-05-30 2019-12-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cancer
WO2021050094A1 (en) * 2019-09-11 2021-03-18 Adverum Biotechnologies, Inc. Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept
EP4041312A4 (en) 2019-10-10 2023-12-20 Kodiak Sciences Inc. METHOD FOR TREATING AN EYE DISORDER

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6019790B2 (ja) 1977-11-18 1985-05-17 株式会社日立製作所 光硬化型接着性組成物とそれを用いて被着体を接着する方法
US4353887A (en) 1979-08-16 1982-10-12 Ciba-Geigy Corporation Divisible tablet having controlled and delayed release of the active substance
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
AU2309692A (en) 1991-07-03 1993-02-11 Cryolife, Inc. Method for stabilization of biomaterials
US5474796A (en) 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
WO1993022336A1 (en) 1992-04-30 1993-11-11 Alpha Therapeutic Corporation Improved solubilization and stabilization of factor viii complex
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
PT694042E (pt) 1993-03-25 2005-02-28 Merck & Co Inc Inibidor do factor de crescimento de celulas endoteliais vasculares
US6811779B2 (en) 1994-02-10 2004-11-02 Imclone Systems Incorporated Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
US6040157A (en) 1994-03-08 2000-03-21 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
GB9410534D0 (en) 1994-05-26 1994-07-13 Lynxvale Ltd Improvements in or relating to growth factor inhibitors
GB9410533D0 (en) 1994-05-26 1994-07-13 Lynxvale Ltd In situ hybridisation and immuno-Chemical localisation of a growth factor
TW438775B (en) 1995-04-07 2001-06-07 Pharmacia & Upjohn Co Llc Novel intermediates and process for the manufacture of camptothecin derivatives (CPT-11) and related compounds
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
JPH09154588A (ja) 1995-10-07 1997-06-17 Toagosei Co Ltd Ｖｅｇｆ結合性ポリペプチド
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
ES2274549T3 (es) 1996-09-24 2007-05-16 MERCK & CO., INC. Compuestos para la inhibicion de la angiogenesis por terapia de genes .
US7312196B2 (en) 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
DE19724793A1 (de) 1997-06-06 1998-12-10 Schering Ag D-mutierte Peptide mit VEGF-Rezeptor blockierenden Eigenschaften
US6075007A (en) 1997-07-17 2000-06-13 Regeneron Pharmaceuticals, Inc. Modified noggin polypeptide and compositions
JPH1180024A (ja) 1997-09-12 1999-03-23 Toagosei Co Ltd 角膜血管新生阻害剤
US6436897B2 (en) 1998-06-01 2002-08-20 Celtrix Pharmaceuticals, Inc. Pharmaceutical formulations for IGF/IGFBP
DE19841985A1 (de) 1998-09-03 2000-03-09 Schering Ag Dialkylsulfonsäure- und Dialkylcarbonsäure-Derivate
US6472179B2 (en) 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
WO2000034337A1 (en) 1998-12-10 2000-06-15 Tsukuba Research Laboratory, Toagosei Co., Ltd. Humanized monoclonal antibodies against vascular endothelial cell growth factor
AP1243A (en) 1999-02-01 2004-02-02 Servier Lab Core tablet for controlled release of gliclazide after oral administration.
DE60011612T2 (de) 1999-04-28 2005-07-07 Board of Regents, The University of Texas System, Austin Zusammensetzungen und Verfahren zur Krebsbehandlung durch die selektive Hemmung von VEGF
WO2000066125A1 (en) 1999-04-29 2000-11-09 Aventis Pharma S.A. Method for treating cancer using camptothecin derivatives and 5-fluorouracil
US7306799B2 (en) 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
US7396664B2 (en) 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US6833349B2 (en) 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
PT1183353E (pt) 1999-06-08 2005-06-30 Regeneron Pharma Polipeptidos quimericos modificados com propriedades farmacocineticas melhoradas
US7303746B2 (en) 1999-06-08 2007-12-04 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with modified chimeric polypeptides
US7001892B1 (en) 1999-06-11 2006-02-21 Purdue Research Foundation Pharmaceutical materials and methods for their preparation and use
DE19938724A1 (de) 1999-08-16 2001-02-22 Tetra Laval Holdings & Finance Vorrichtung zur Herstellung von Kunststoffbehältern mittels Streckblasformen
GB0008269D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
US6500633B1 (en) 2000-04-26 2002-12-31 Atairgin Technologies, Inc. Method of detecting carcinomas
GT200100079A (es) 2000-05-10 2001-12-31 Metodo para regular la angiogenesis utilizando proteina ryk
PT1324776E (pt) 2000-10-12 2009-12-23 Genentech Inc Formulações de proteína concentradas de viscosidade reduzida
US20030092019A1 (en) 2001-01-09 2003-05-15 Millennium Pharmaceuticals, Inc. Methods and compositions for diagnosing and treating neuropsychiatric disorders such as schizophrenia
US20040023864A1 (en) 2001-05-09 2004-02-05 Steve Roczniak Method of regulating angiogenesis using ryk protein
WO2003009817A2 (en) 2001-07-25 2003-02-06 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
DE60314378T2 (de) 2002-03-01 2008-02-28 Pfizer Italia S.R.L. Kristalline polymorphe form von irinotecanhydrochlorid
JP2004006671A (ja) 2002-03-22 2004-01-08 Sanyo Electric Co Ltd 電荷結合素子およびその製造方法
BRPI0408749B1 (pt) 2003-03-28 2016-10-04 Regeneron Pharma uso do antagonista de vegf vegfr1r2-fc delta c1(a)
HUE030579T2 (en) 2003-04-04 2017-05-29 Genentech Inc High Concentration Antibody And Protein Products
EP1626989A2 (en) 2003-05-28 2006-02-22 Regeneron Pharmaceuticals, Inc. Method of treating corneal transplant rejection by using vegf antagonists
US7300654B2 (en) 2003-05-28 2007-11-27 Regeneron Pharmaceuticals, Inc. Method of treating corneal transplant rejection in high risk keratoplasty patients
US7186699B2 (en) 2003-06-03 2007-03-06 Cell Genesys, Inc. Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
US7354578B2 (en) 2003-06-06 2008-04-08 Regeneron Pharmaceuticals, Inc. Method of tumor regression with VEGF inhibitors
US7399612B2 (en) 2003-06-30 2008-07-15 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
AR046510A1 (es) 2003-07-25 2005-12-14 Regeneron Pharma Composicion de un antagonista de vegf y un agente anti-proliferativo
US20050196340A1 (en) 2003-08-06 2005-09-08 Jocelyn Holash Use of a VEGF antagonist in combination with radiation therapy
AU2004264891A1 (en) 2003-08-06 2005-02-24 Regeneron Pharmaceuticals, Inc. Use of a VEGF antagonist in combination with radiation therapy
WO2005017734A1 (ja) 2003-08-14 2005-02-24 Fujitsu Limited コンピュータ装置および集合サーバ装置
CA2903196A1 (en) 2003-08-27 2005-03-10 Ophthotech Corporation Combination therapy for the treatment of ocular neovascular disorders
ATE423670T1 (de) 2003-11-06 2009-03-15 Nestle Waters Man & Technology Herstellungsverfahren von behältern aus polyesterharz
CA2545187A1 (en) 2003-11-10 2005-05-26 Greenville Hospital System Vegf receptor antagonists
WO2005072772A1 (en) 2004-01-30 2005-08-11 Suomen Punainen Risti Veripalvelu Pharmaceutical compositions
US7354580B2 (en) 2004-06-10 2008-04-08 Regeneron Pharmaceuticals, Inc. Method of administering and using VEGF inhibitors for the treatment of human cancer
US20050281822A1 (en) 2004-06-18 2005-12-22 Cedarbaum Jesse M Method of administering and using VEGF inhibitors for the treatment of malignant pleural effusion
CA2567795C (en) 2004-07-30 2013-06-11 Regeneron Pharmaceuticals, Inc. Methods of treating type i diabetes by blocking vegf-mediated activity
NZ596663A (en) 2004-10-21 2013-07-26 Genentech Inc Use of vegf antagonists in intraocular neovascular disease treatment
FR2878749B1 (fr) 2004-12-03 2007-12-21 Aventis Pharma Sa Combinaisons antitumorales contenant en agent inhibiteur de vegt et du 5fu ou un de ses derives
AU2006214658A1 (en) 2005-02-02 2006-08-24 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a VEGF inhibitor
JP2008537538A (ja) 2005-02-11 2008-09-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｖｅｇｆ拮抗剤及び降圧剤の治療的組み合わせ
WO2006099154A1 (en) 2005-03-11 2006-09-21 Regeneron Pharmaceuticals, Inc. Treating anemia by inhibition of vegf
ES2633574T3 (es) 2005-03-25 2017-09-22 Regeneron Pharmaceuticals, Inc. Formulaciones de antagonistas de VEGF
WO2007022101A2 (en) 2005-08-12 2007-02-22 Regeneron Pharmaceuticals, Inc. Treatment of diseases by subcutaneous administration of a vegf antagonist
US7354582B2 (en) 2006-03-10 2008-04-08 Regeneron Pharmaceuticals, Inc. Use of VEGF antagonists for the treatment of malignant gliomas
CA2654510C (en) 2006-06-16 2015-03-17 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations suitable for intravitreal administration
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
EP2136630A4 (en) 2007-03-23 2010-06-02 Precision Therapeutics Inc METHODS FOR ASSESSING ANGIOGENIC POTENTIAL IN CULTURE
FR2918279B1 (fr) 2007-07-05 2010-10-22 Aventis Pharma Sa Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan
CN100546578C (zh) * 2007-08-10 2009-10-07 河北医科大学 一种抗癌药物组合物及其在制备抗癌药物中的应用
EP2207791B2 (en) 2007-10-04 2019-08-07 Onyx Therapeutics, Inc. Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
JP2011505145A (ja) 2007-11-30 2011-02-24 ブライアン ピー． シュナイダー， Ｖｅｇｆ多型および抗脈管形成治療
EP2143542A1 (fr) 2008-07-07 2010-01-13 Nestec S.A. Procédé et dispositif de conditionnement d'un liquide alimentaire
FR2933702A1 (fr) 2008-07-08 2010-01-15 Sanofi Aventis Antagonistes specifiques du recepteur fgf-r4
WO2010022201A2 (en) 2008-08-22 2010-02-25 Osteogenex Inc. Folinic acid derivatives for promoting bone growth
WO2010042903A1 (en) 2008-10-09 2010-04-15 Alfagene Bioscience, Inc Use and identification of biomarkers for gastrointestinal diseases
MX2011004763A (es) 2008-11-05 2011-06-01 Genentech Inc Polimorfismos geneticos en la degeneracion macular relacionada con la edad.
SG174963A1 (en) 2009-03-31 2011-11-28 Roche Glycart Ag Treatment of cancer with a humanized anti-egfr igg1 antibody and irinotecan
US20120100134A1 (en) 2009-04-24 2012-04-26 University Of Southern California Genetic variants in angiogenesis pathway associated with clinical outcome
CN102741126B (zh) 2009-07-31 2016-02-24 阿美科有限责任公司 塑料容器
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
AU2012228544B2 (en) 2011-02-23 2015-06-11 Sanofi Single nucleotide polymorphisms in the promoter of VEGFA gene and their use as predictive markers for anti-VEGF treatments
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
JP6019790B2 (ja) 2012-06-19 2016-11-02 富士電機株式会社 接合方法及び接合部材
EA201590305A1 (ru) 2012-08-02 2015-06-30 Санофи Изделие производства, включающее афлиберцепт или зив-афлиберцепт
DK3170005T3 (da) 2014-07-18 2019-07-08 Sanofi Sa Fremgangsmåde til forudsigelse af resultatet af en behandling med aflibercept hos en patient, der mistænkes for at lide af cancer
KR102652347B1 (ko) 2016-01-25 2024-03-27 사노피 혈장 바이오마커 수준의 측정에 의해 암을 앓고 있는 것으로 의심되는 환자의 아플리베르셉트로의 치료 결과를 예측하는 방법

Also Published As

Publication number Publication date
DK2701724T3 (en) 2017-09-11
PE20140616A1 (es) 2014-05-24
ZA201308821B (en) 2015-01-28
PL2701724T3 (pl) 2017-11-30
TW201247220A (en) 2012-12-01
TWI599369B (zh) 2017-09-21
CL2013003082A1 (es) 2014-05-16
EP3210617A1 (en) 2017-08-30
CN103608029A (zh) 2014-02-26
AU2012247530B2 (en) 2017-05-11
PT2701724T (pt) 2017-08-18
JP2014513089A (ja) 2014-05-29
EA201391577A1 (ru) 2014-03-31
ECSP13013044A (es) 2014-01-31
JP6114257B2 (ja) 2017-04-12
KR102002653B1 (ko) 2019-07-24
CA2833592A1 (en) 2012-11-01
HRP20171216T1 (hr) 2017-10-20
JO3283B1 (ar) 2018-09-16
DOP2013000248A (es) 2014-02-28
IL228947B (en) 2018-01-31
EP2701724A1 (en) 2014-03-05
BR112013027356A2 (pt) 2016-11-29
MA35130B1 (fr) 2014-05-02
NI201300112A (es) 2014-02-28
AU2012247530A1 (en) 2013-05-02
UA114708C2 (uk) 2017-07-25
MX2013012387A (es) 2014-12-05
SI2701724T1 (sl) 2017-10-30
UY34036A (es) 2012-11-30
WO2012146610A1 (en) 2012-11-01
HUE034288T2 (en) 2018-02-28
MX341348B (es) 2016-08-17
KR20190088568A (ko) 2019-07-26
LT2701724T (lt) 2017-09-11
NZ617573A (en) 2015-11-27
RS56177B1 (sr) 2017-11-30
SG194613A1 (en) 2013-12-30
IL257179A (en) 2018-03-29
IL228947A0 (en) 2013-12-31
SG10201610829UA (en) 2017-02-27
CY1120382T1 (el) 2019-07-10
US11033606B2 (en) 2021-06-15
KR20140036193A (ko) 2014-03-25
PE20171516A1 (es) 2017-10-20
ES2637074T3 (es) 2017-10-10
CO6811861A2 (es) 2013-12-16
EP2701724B1 (en) 2017-05-24
EA025182B1 (ru) 2016-11-30
CR20130547A (es) 2014-02-18
GT201300260A (es) 2015-02-09
US20140051642A1 (en) 2014-02-20

Similar Documents

Publication Publication Date Title
AR086051A1 (es) Metodo para tratar el cancer colorrectal, composicion que comprende aflibercept, acido folinico, 5-fluorouracilo (5-fu) e irinotecano (folfiri), articulo manufacturado, kit
MX2021004821A (es) Uso de antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinacion con radioterapia.
MX2021000609A (es) Métodos de tratamiento con fármacos sustrato para cyp3a4.
EA201800199A1 (ru) Применение akkermansia muciniphila для лечения метаболических расстройств, увеличения расхода энергии и снижения веса, композиции, лекарственное стедство
EA201491584A1 (ru) Способы лечения немелкоклеточного рака легких c применением комбинированного лечения с ингибитором киназы tor
MX2016005532A (es) Metodos para usar oxido nitrico en un estado de plasma para tratar condiciones medicas y enfermedades.
MX2015010791A (es) Metodos para tratar el cancer y prevenir la resistencia a farmacos.
MX2017017138A (es) Conjugados homogeneos especificos de sitio con inhibidores de ksp.
RU2018135973A (ru) Фармацевтическая комбинация, содержащая метроформин и дигидрокверценин, и ее применение для лечения рака
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
PH12017501300A1 (en) Novel iodophor composition and methods of use
PH12017500392A1 (en) Medical treatments based on anamorelin
TN2016000498A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine.
MX2022014792A (es) Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
PH12018501769A1 (en) Medicament for treatment of diabetic foot infections
EA201491629A1 (ru) Способы лечения рака с использованием липоплатина
UA97663U (uk) Спосіб лікування вертеброгенного больового корінцевого синдрому у хворих на розсіяний склероз
RU2012158011A (ru) Метод и композиция для лечения рака
PL408261A1 (pl) Plaster zawierający substancje przeciwbólowe jako innowacyjna forma aplikacji , łagodzenia oraz leczenia bólu
MX2011011881A (es) Uso de la delfinidina y sus derivados para preparar un medicamento para el tratamiento de la prediabetes y diabetes.
RU2010116989A (ru) Способ лечения саркоидоза кожи
RU2010147965A (ru) Способ лечения флегмон тыльной поверхности кисти у детей

Legal Events

Date Code Title Description
FB Suspension of granting procedure